458
Habek M, Borovecki F, Brinar VV. Genomics in multiple sclerosis. Clin Neurol Neurosurg.
2010;112:621–4.
He ZW, Qu J, Zhang Y, et al. PRRT2 mutations are related to febrile seizures in epileptic patients.
Int J Mol Sci. 2014;15:23408–17.
Hecker M, Goertsches RH, Fatum C, et al. Network analysis of transcriptional regulation in
response to intramuscular interferon-β-1a multiple sclerosis treatment. Pharmacogenomics
J. 2012;12:134–46.
Holbach KH, Wassmann H, Hohelochter KL, Jain KK. Differentiation between reversible and
irreversible post-stroke changes in the brain tissue and its relevance to cerebrovascular surgery.
Surg Neurol. 1977;7:324–31.
Hongo J, Nakaaki S, Shinagawa Y, et al. SPECT-identifi ed neuroanatomical predictor of the cogni-
tive effects of donepezil treatment in patients with Alzheimer’s disease. Dement Geriatr Cogn
Disord. 2008;26:556–66.
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium
2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in
multiple sclerosis. Nature 2011;476:214–9.
Jahanshad N, Rajagopalan P, Hua X, et al. Genome-wide scan of healthy human connectome dis-
covers SPON1 gene variant infl uencing dementia severity. Proc Natl Acad Sci U S A.
2013;110:4768–73.
Jain KK. Role of neuroproteomics in CNS drug discovery. Drug Discov Today Targets.
2002;1:95–101.
Jain KK. Personalized neurology. Pers Med. 2005;1:15–21.
Jain KK. Textbook of hyperbaric medicine. 5th ed. Göttingen: Hogrefe & Huber; 2009.
Jain KK. The handbook of neuroprotection. New York: Humana/Springer; 2011.
Jain KK. Neuroproteomics. In: Jain KK, editor. Applications of biotechnology in neurology.
New York: Springer/Humana; 2013. p. 17–48.
Jain KK. Alzheimer’s disease: drugs, markets and companies. Basel: Jain PharmaBiotech;
2015a.
Jain KK. Cell therapy: technologies, markets and companies. Basel: Jain PharmaBiotech; 2015b.
Jain KK. Role of neurogenomics in the development of personalized neurology. In: Jain KK, edi-
tor. Applied neurogenomics. New York: Springer; 2015c.
Jain KK. Pain therapeutics. Basel: Jain PharmaBiotech; 2015d.
Jové M, Portero-Otín M, Naudí A, et al. Metabolomics of human brain aging and age-related neu-
rodegenerative diseases. J Neuropathol Exp Neurol. 2014;73:640–57.
Kappos L, Achtnichts L, Dahlke F, et al. Genomics and proteomics: role in the management of
multiple sclerosis. J Neurol 2005;252(Suppl 3):iii21–7.
Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treat-
ment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up
analysis of the BENEFIT study. Lancet. 2007;370:389–97.
Kearney JA. Advances in epilepsy genetics and genomics. Epilepsy Curr. 2012;12:143–6.
Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the
voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among pheno-
type, genotype, and mRNA expression. Pharmacogenet Genomics. 2008;18:989–98.
Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365:919–26.
Lill CM. Recent advances and future challenges in the genetics of multiple sclerosis. Front Neurol.
2014;5:130.
Lister R, Mukamel EA, Nery JR, et al. Global epigenomic reconfi guration during mammalian
brain development. Science. 2013;341:1237905.
Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treat-
ment of epilepsy. Epilepsia. 2009;50:1–23.
Loup F, Picard F, Yonekawa Y, et al. Selective changes in GABAA receptor subtypes in white mat-
ter neurons of patients with focal epilepsy. Brain. 2009;132:2449–63.
Ma CL, Wu XY, Zheng J, et al. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms
with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacoge-
nomics. 2014;15:1323–36.
12 Personalized Management of Neurological Disorders